CCAT2 (Colon Cancer Associated Transcript 2)

This study systematically reviews recent findings on CCAT2's role in the development and progression of breast, ovarian, endometrial, and cervical cancers, elucidates the underlying molecular mechanisms, and evaluates its potential as a diagnostic and prognostic biomarker. Furthermore, the translational potential of CCAT2 as a therapeutic target is discussed, highlighting opportunities for improving clinical outcomes in these malignancies.

Our findings suggest that these selected lncRNA-related SNPs may contribute to colorectal cancer risk in a sex- and site-specific manner. These preliminary results warrant further validation in larger, independent cohorts and functional studies.

CCAT2 gene polymorphisms (rs3843549 A > G and rs6983267 T > G) were not associated with susceptibility to neuroblastoma. However, the accuracy of this conclusion may be limited by various confounding factors. Future analyses would benefit from a more comprehensive approach that accounts for additional variables.

A combined analysis of polymorphisms rs4430796 and rs1859962 has the potential to serve as a basis for the genetic stratification of PR risk in the Russian population. The identified genomic combinations have potential as marker panels for screening and differentiation of PC and BPH, as well as for the development of personalised approaches in oncology.

In the present study, we reviewed recent literature concerning lncRNA CCAT2's role in the development and progression of different GI cancers, including colorectal, gastric, hepatocellular, and oropharyngeal cancer, its interaction with cancer-related molecular mechanisms, and evaluate its potential as a diagnostic and prognostic biomarker in GI patients. In addition, this study shows that CCAT2 can be applied as a novel target for treatment strategies in gastrointestinal cancers.

Our findings validated rs10795668 (LOC10537640), rs4939827 (SMAD7), rs6066825 (PREX1), and rs6983267 (CCAT2) polymorphisms in CRC risk among Brazilians and suggest that lower Asian and African ancestries might influence CRC susceptibility.

Our findings suggest that c-Myc and LncRNAs (TCF7L2, PVT1, and CCAT2) are upregulated and miR-33 is downregulated in OSCC compared to OLP samples. These genes may serve as potential genetic biomarkers for diagnosis and prediction of clinicopathological features of OSCC.

The study presented in the manuscript aims to explore the involvement of lncRNAs in GBM, focusing on their roles in tumor progression, proliferation, invasion, and potential implications for early detection and immunotherapy. The research seeks to elucidate the mechanisms by which specific lncRNAs influence GBM characteristics and highlight their potential as therapeutic targets or biomarkers in managing this aggressive form of brain cancer.

17 (2024): e70169, https://doi.org/10.1002/cam4.70169...The authors further stated that, upon reviewing the published article, they discovered multiple issues related to image overlap and redundancy. All parties agree that the overlapping and duplicated images constitute a major error in the article and it must be retracted.

Due to their presence in biological fluids and tissues, they may serve as novel biomarkers. Enhancing PCa treatments mitigates resistance to chemotherapy and radiation.

CCAT2 plays a crucial role in CRC progression by modulating the ERK and Wnt signaling pathways through its interaction with GNB2. These findings highlight the importance of CCAT2 as a key regulatory element in the mechanisms underlying CRC proliferation and metastasis.